What is the best method for preventing respiratory syncytial virus (RSV) in at-risk infants?

Palivizumab prophylaxis is the most effective method for preventing respiratory syncytial virus (RSV) in at-risk infants. This monoclonal antibody is specifically designed to provide passive immunity against RSV, thereby reducing the risk of severe disease in high-risk populations, such as infants born prematurely or those with certain underlying health conditions like congenital heart disease or chronic lung disease.

While hand hygiene practices are essential in preventing the transmission of numerous infectious agents, they are not specific to RSV and do not offer targeted protection for at-risk infants. Vaccination against RSV is currently under development, but as of now, there is no approved vaccine available for general use in infants. Breastfeeding provides many health benefits and contributes to the infant's immune system, but it does not offer specific protection against RSV.

Thus, Palivizumab prophylaxis stands out as the only targeted method that effectively lowers the likelihood of severe RSV infection in vulnerable infants, making it the best choice for preventing this virus in at-risk populations.